{"id":19796,"date":"2024-05-28T14:11:34","date_gmt":"2024-05-28T14:11:34","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/?p=19796"},"modified":"2024-05-29T10:17:22","modified_gmt":"2024-05-29T10:17:22","slug":"63rd-afi-symposium-roberto-de-lucas-interview","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/afi-interview\/63rd-afi-symposium-roberto-de-lucas-interview\/","title":{"rendered":"63rd AFI Symposium \u2013 Roberto de Luca\u2019s interview"},"content":{"rendered":"

The complexity of the pharmaceutical supply chain<\/strong> becomes increasingly complex following the developments that characterize this sector, about types of products, regulations, sales channels, globalization.<\/p>\n

\n
\n
\n
\n
\n
\n

Among the various phases of the supply chain, possible and new critical issues characterize in particular the management of medicines in the distribution phase<\/strong>, therefore when the drugs leave the production plant.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n

The second session of the 63rd AFI Symposium, entitled “The supply chain…the work in progress<\/em>“, will analyze these aspects, animating the discussion from a new point of view, which seeks to involve all the actors in the supply chain<\/strong> and not just the pharmaceutical companies.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n

As Roberto de Luca, coordinator of the AFI Supply Chain Studies group and moderator of the session, reminds us, the need is to involve all the operators who manage the subsequent phases of the process: Primary distribution<\/strong> (multi-agent warehouses), Intermediate distribution<\/strong> (wholesalers), Tran<\/strong><\/span>sport<\/strong>, Hospital pharmacies<\/strong> and Community pharmacies<\/strong>.<\/p>\n<\/div>\n

Furthermore, during the video interview, De Luca underlines that in the transport field it is necessary to identify the right strategies, especially from a regulatory point of view. The need is to define responsibilities, identify key figures and issue applicable directives without blocking the process<\/strong>.<\/span><\/p>\n

The growing complexity of pharmaceutical productions and the transformations linked to innovations require, in fact, greater attention and the need to encourage discussion between all parties<\/strong>.<\/p>\n